{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:51:47Z","timestamp":1793407907748,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R21CA181935"],"award-info":[{"award-number":["5R21CA181935"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5079-x","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:07:47Z","timestamp":1543241267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"K. G.","family":"Ewens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Richards-Yutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4527-3216","authenticated-orcid":false,"given":"A.","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"issue":"9","key":"5079_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097\u2013112.","journal-title":"Oncogene."},{"issue":"1","key":"5079_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1749-6632.1999.tb09414.x","volume":"886","author":"DE Jensen","year":"1999","unstructured":"Jensen DE, Rauscher FJ. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci. 1999;886(1):191\u20134.","journal-title":"Ann N Y Acad Sci."},{"issue":"17","key":"5079_CR3","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","volume":"68","author":"KH Ventii","year":"2008","unstructured":"Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Can Res. 2008;68(17):6953\u201362.","journal-title":"Can Res"},{"key":"5079_CR4","unstructured":"OMIM: Tumor predisposition syndrome; TPDS. \n                    https:\/\/www.omim.org\/entry\/614327\n                    \n                  ."},{"key":"5079_CR5","unstructured":"Pilarski R, Rai K, Cebulla C, Abdel-Rahman M. BAP1 Tumor Predisposition Syndrome. 2016 Oct 13 In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK390611\/\n                    \n                  ."},{"key":"5079_CR6","doi-asserted-by":"crossref","unstructured":"Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013; 13:371-371.","DOI":"10.1186\/1471-2407-13-371"},{"issue":"1","key":"5079_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bfgp\/elm007","volume":"6","author":"D Angeloni","year":"2007","unstructured":"Angeloni D. Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genomics. 2007;6(1):19\u201339.","journal-title":"Brief Funct Genomics."},{"issue":"9","key":"5079_CR8","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal Melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135.","journal-title":"Ophthalmology."},{"issue":"3","key":"5079_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cge.12630","volume":"89","author":"K Rai","year":"2016","unstructured":"Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285\u201394.","journal-title":"Clin Genet"},{"issue":"11","key":"5079_CR10","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"6","key":"5079_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2214\/ajr.157.6.1950883","volume":"157","author":"JG Lorigan","year":"1991","unstructured":"Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am J Roentgenol. 1991;157(6):1279\u201381.","journal-title":"Am J Roentgenol."},{"issue":"2","key":"5079_CR12","first-page":"313","volume":"42","author":"Y Aalto","year":"2001","unstructured":"Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(2):313\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"5079_CR13","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/eye.2009.235","volume":"23","author":"B Damato","year":"2009","unstructured":"Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye. 2009;23(12):2152\u201362.","journal-title":"Eye"},{"issue":"7","key":"5079_CR14","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1167\/iovs.08-3165","volume":"50","author":"B Damato","year":"2009","unstructured":"Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50(7):3048\u201355.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"5079_CR15","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1167\/iovs.13-12195","volume":"54","author":"KG Ewens","year":"2013","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Al-Dahmash S, De Luca MC, Bianciotto CG, et al. Genomic profile of 320 uveal melanoma cases: Chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci. 2013;54(8):5721\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"5079_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989\u201398.","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"5079_CR17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","volume":"124","author":"CL Shields","year":"2017","unstructured":"Shields CL, Say EAT, Hasanreisoglu M, Saktanasate J, Lawson BM, Landy JE, et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: The 2017 Harry S. Gradle Lecture. Ophthalmology. 2017;124(10):1523\u201331.","journal-title":"Gradle Lecture. Ophthalmology."},{"issue":"5","key":"5079_CR18","first-page":"609","volume":"124","author":"CL Shields","year":"2017","unstructured":"Shields CL, Say EAT, Hasanreisoglu M, Saktanasate J, Lawson BM, Landy JE, et al. Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients: The 2016 W. Richard Green Lecture. Ophthalmology. 2017;124(5):609\u201318.","journal-title":"Richard Green Lecture. Ophthalmology"},{"issue":"20","key":"5079_CR19","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","volume":"64","author":"MD Onken","year":"2004","unstructured":"Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Can Res. 2004;64(20):7205\u20139.","journal-title":"Can Res."},{"issue":"4","key":"5079_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","volume":"12","author":"MD Onken","year":"2010","unstructured":"Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461\u20138.","journal-title":"J Mol Diagn."},{"issue":"5","key":"5079_CR21","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1158\/1078-0432.CCR-06-2401","volume":"13","author":"LA Worley","year":"2007","unstructured":"Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Can Res. 2007;13(5):1466\u201371.","journal-title":"Clin Can Res."},{"issue":"7","key":"5079_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","volume":"134","author":"CL Decatur","year":"2016","unstructured":"Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: Associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728\u201333.","journal-title":"JAMA Ophthalmol."},{"issue":"6009","key":"5079_CR23","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410\u20133.","journal-title":"Science."},{"issue":"7","key":"5079_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/bjc.2014.417","volume":"111","author":"H Kalirai","year":"2014","unstructured":"Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer. 2014;111(7):1373\u201380.","journal-title":"Br J Cancer."},{"issue":"10","key":"5079_CR25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","volume":"27","author":"AE Koopmans","year":"2014","unstructured":"Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM. Vaarwater et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27(10):1321\u201330.","journal-title":"Mod Pathol."},{"issue":"7","key":"5079_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/PAT.0000000000000002","volume":"45","author":"AA Shah","year":"2013","unstructured":"Shah AA, David Bourne T, Murali R. BAP1 protein loss by immunohistochemistry: A potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology. 2013;45(7):651\u20136.","journal-title":"Pathology."},{"issue":"6","key":"5079_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/PAS.0000000000000645","volume":"40","author":"JA van de Nes","year":"2016","unstructured":"van de Nes JA, Nelles J, Kreis S, Metz CH, Hager T, Lohmann DR, et al. Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma. Am J Surg Pathol. 2016;40(6):796\u2013805.","journal-title":"Am J Surg Pathol."},{"issue":"12","key":"5079_CR28","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1136\/bjophthalmol-2014-305047","volume":"98","author":"TH van Essen","year":"2014","unstructured":"van Essen TH, van Pelt SI, Versluis M, Bronkhorst IHG, van Duinen SG, Marinkovic M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98(12):1738\u201343.","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"5079_CR29","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","volume":"123","author":"S Yavuzyigitoglu","year":"2016","unstructured":"Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations: A distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118\u201328.","journal-title":"Ophthalmology"},{"issue":"8","key":"5079_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","volume":"133","author":"MP Gupta","year":"2015","unstructured":"Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133(8):881\u20137.","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"5079_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/pcmr.12046","volume":"26","author":"LG Aoude","year":"2013","unstructured":"Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res. 2013;26(2):278\u20139.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"4","key":"5079_CR32","doi-asserted-by":"publisher","first-page":"e35295","DOI":"10.1371\/journal.pone.0035295","volume":"7","author":"C-NJ Njauw","year":"2012","unstructured":"Njauw C-NJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE. 2012;7(4):e35295.","journal-title":"PLoS ONE."},{"issue":"5","key":"5079_CR33","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.ophtha.2016.01.008","volume":"123","author":"JA Turunen","year":"2016","unstructured":"Turunen JA, Markkinen S, Wilska R, Saarinen S, Raivio V, T\u00e4ll M, Lehesjoki A-E, et al. BAP1 germline mutations in finnish patients with uveal melanoma. Ophthalmology. 2016;123(5):1112\u20137.","journal-title":"Ophthalmology."},{"issue":"1","key":"5079_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","volume":"9","author":"MG Field","year":"2018","unstructured":"Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nature Commun. 2018;9(1):116.","journal-title":"Nature Commun."},{"issue":"8","key":"5079_CR35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/archopht.125.8.1017","volume":"125","author":"CL Shields","year":"2007","unstructured":"Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD. Lectureship. Arch Ophthalmol. 2007;125(8):1017\u201324.","journal-title":"Lectureship. Arch Ophthalmol."},{"issue":"2","key":"5079_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10689-016-9865-9","volume":"15","author":"MH Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman MH, Rai K, Pilarski R, Davidorf FH, Cebulla CM. Germline BAP1 mutations misreported as somatic based on tumor-only testing. Familial Cancer. 2016;15(2):327\u201330.","journal-title":"Familial Cancer."},{"issue":"8","key":"5079_CR37","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1167\/iovs.14-14550","volume":"55","author":"KG Ewens","year":"2014","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2014;55(8):5160\u20137.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"5079_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/humu.22488","volume":"35","author":"Z Chen","year":"2014","unstructured":"Chen Z, Moran K, Richards-Yutz J, Toorens E, Gerhart D, Ganguly T, et al. Enhanced sensitivity for detection of low-level germline mosaic RB1 mutations in sporadic retinoblastoma cases using deep semiconductor sequencing. Hum Mut. 2014;35(3):384\u201391.","journal-title":"Hum Mut."},{"issue":"5","key":"5079_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med."},{"issue":"4","key":"5079_CR40","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/bjc.2013.804","volume":"110","author":"M Dono","year":"2014","unstructured":"Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer. 2014;110(4):1058\u201365.","journal-title":"Br J Cancer."},{"issue":"4","key":"5079_CR41","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.18632\/oncotarget.6614","volume":"7","author":"P Johansson","year":"2016","unstructured":"Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624\u201331.","journal-title":"Oncotarget."},{"issue":"2","key":"5079_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204\u201320.","journal-title":"Cancer Cell."},{"issue":"1","key":"5079_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/aos.13452","volume":"96","author":"KM Staby","year":"2018","unstructured":"Staby KM, Gravdal K, M\u00f8rk SJ, Heegaard S, Vintermyr OK, Krohn J. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. Acta Ophthalmol. 2018;96(1):31\u20138.","journal-title":"Acta Ophthalmol."},{"issue":"8","key":"5079_CR44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Maszhofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45(8):933\u20136.","journal-title":"Nat Genet."},{"issue":"3","key":"5079_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cge.12501","volume":"88","author":"KA Wadt","year":"2015","unstructured":"Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet. 2015;88(3):267\u201372.","journal-title":"Clin Genet"},{"issue":"3","key":"5079_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/CMR.0000000000000152","volume":"25","author":"ACH van Engen-van Grunsven","year":"2015","unstructured":"van Engen-van Grunsven ACH, Baar MP, Pfundt R, Rijntjes J, K\u00fcsters-Vandevelde HVN, Delbecq A-L, et al. Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas. Melanoma Res. 2015;25(3):200\u20139.","journal-title":"Melanoma Res."},{"issue":"6","key":"5079_CR47","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","volume":"92","author":"T Popova","year":"2013","unstructured":"Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d\u2019Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92(6):974\u201380.","journal-title":"Am J Hum Genet."},{"issue":"5","key":"5079_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cancergen.2013.05.018","volume":"206","author":"M Cheung","year":"2013","unstructured":"Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013;206(5):206\u201310.","journal-title":"Cancer Genet."},{"issue":"3","key":"5079_CR49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molonc.2013.02.004","volume":"7","author":"C Laurent","year":"2013","unstructured":"Laurent C, Gentien D, Piperno-Neumann S, N\u00e9mati F, Nicolas A, Tesson B, et al. Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncology. 2013;7(3):625\u201336.","journal-title":"Mol Oncology."},{"issue":"10","key":"5079_CR50","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018\u201321.","journal-title":"Nat Genet"},{"issue":"2","key":"5079_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/gcc.22129","volume":"53","author":"R Pilarski","year":"2014","unstructured":"Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177\u201382.","journal-title":"Genes Chromosomes Cancer."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:31:07Z","timestamp":1589463067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5079"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5079-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained at the time of testing the tumor samples from all individuals. This research was approved by the Institutional Review Board of the University of Pennsylvania, and is in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1172"}}